RedHill Biopharma has announced a research collaboration with the NIH. The focus will be RedHill’s new experimental treatment for Ebola, after encouraging results in preliminary studies.
The Ebola outbreak of 2014 in West Africa highlighted the need for a therapy against this infectious disease, which has mortality rate ranging from 25% to 90%.
The crisis spurred a number of new developments, including many institutionally-backed programs. For example, Bavarian Nordic (Denmark) got a €50M loan from the European Union and the WHO sponsored the trial of MSD‘s vaccine, which has shown a 100% success rate in preventing Ebola. And a US Defense Agency is supporting Humab’s Ebola antibody, which could be an Ebola cure for people already infected.
Even in the aftermath of this epidemic, interest in developing a treatment for Ebola hasn’t died down. RedHill Biopharma (based in Tel-Aviv, Israel) has now announced a research collaboration with the National Institute of Health (NIH) to evaluate its new experimental therapy.